• Alex Keown
• 26 Jun, 2019

Eli Lilly’s type 2 diabetes drug Trulicity hit the mark in a late-stage trial that showed higher doses of the medication significantly reduced A1C from baseline compared to the once-per-week dose of Trulicity currently on the market. Trulicity (dulaglutide) is currently approved for type 2 diabetes in a 1.5 mg dose. The medication is approved to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
Read more...